BOSTON, Dec. 17, 2025 (GLOBE NEWSWIRE) -- Entrada Therapeutics, Inc. (Nasdaq: TRDA) today announced that Dipal Doshi, Chief Executive Officer, will deliver a company presentation at the 44th Annual J.P. Morgan Healthcare Conference on Wednesday, January 14, 2026, at 3:45 PM PT (6:45 PM ET). A live webcast will be available on the Presentations portion of Entrada’s Investor Relations website at https://ir.entradatx.com. The webcast will be archived and available for replay for 30 days after the event. About ...

Entrada Therapeutics ( TRDA ) reported a 3Q25 GAAP EPS loss of -$1.06 along with a revenue figure of $1.6 million. Since earnings on November 6th, the stock is up about 25%. In the report, there was a pretty sharp declineI hold a Master’s degree in Cell Biology and began my career working for several years as a lab technician in a drug discovery clinic, where I gained extensive hands-on experience in cell culture, assay development, and therapeutic research. That scientific foundation gave me an appreciatio ...

Financial Performance - Collaboration revenue decreased significantly to $1.614 million in Q3 2025 from $19.570 million in Q3 2024, a decline of $17.956 million[118]. - Net loss for Q3 2025 was $44.134 million, compared to a net loss of $14.032 million in Q3 2024, an increase in loss of $30.102 million[118]. - For the nine months ended September 30, 2025, collaboration revenue was $24.1 million, a significant decrease of $149.3 million from $173.4 million in 2024, primarily due to fewer costs incurred for VX-670[126]. - Net loss for the nine months ended September 30, 2025, was $104.6 million, compared to a net income of $64.5 million for the same period in 2024, a decline of $169.1 million[125]. Expenses - Research and development expenses increased to $38.361 million in Q3 2025 from $31.257 million in Q3 2024, an increase of $7.104 million[118]. - General and administrative expenses rose to $10.304 million in Q3 2025 compared to $9.971 million in Q3 2024, an increase of $333,000[118]. - Total operating expenses for Q3 2025 were $48.665 million, up from $41.228 million in Q3 2024, reflecting an increase of $7.437 million[118]. - Total research and development expenses for the nine months ended September 30, 2025, were $108.3 million, an increase of $16.4 million from $91.9 million in 2024, driven by higher direct research costs[127]. Cash and Funding - As of September 30, 2025, the company had cash, cash equivalents, and marketable securities totaling $326.8 million, sufficient to fund operations into Q3 2027[99]. - The company has raised over $850.0 million in gross proceeds from stock sales and collaborations since inception, with $326.8 million in cash and marketable securities as of September 30, 2025[140]. - The company plans to file a new shelf registration statement to replace the prior one that will expire on November 7, 2025, allowing for future equity offerings[142]. - The company anticipates significant future funding requirements due to ongoing research and development expenses[152]. Strategic Developments - The company has two product candidates, ENTR-601-44 and ENTR-601-45, in clinical development for Duchenne muscular dystrophy (DMD)[99]. - The company expects to report data from the first cohort of the ENTR-601-44 study in Q2 2026 and from the first patient cohort of ENTR-601-45 in mid-2026[101]. - The company anticipates filing for EU regulatory clearance for ENTR-601-50 in the second half of 2026 and for ENTR-601-51 in 2026[100]. - Vertex Pharmaceuticals is on track to complete enrollment and dosing in the VX-670 trial in the first half of 2026[105]. Workforce and Operational Changes - A strategic plan approved on April 29, 2025, led to a workforce reduction of approximately 20%, incurring charges of $1.9 million[158]. - The company has entered into contracts with CROs and third-party manufacturers for preclinical research, which are cancellable upon prior written notice[156]. - The company remains classified as an "emerging growth company" and a "smaller reporting company," allowing it to take advantage of reduced reporting requirements[159][162]. Other Financial Metrics - Total interest and other income decreased to $3.6 million for the three months ended September 30, 2025, down from $5.8 million in 2024, reflecting changes in interest earned from debt securities and a decrease in marketable securities[123]. - For the nine months ended September 30, 2025, the company reported a net cash used in operating activities of $96.3 million, driven by a net loss of $104.6 million[145]. - The company generated $87.7 million from investing activities for the nine months ended September 30, 2025, primarily from $212.1 million in maturities of marketable securities[147]. - Net cash provided by financing activities was $0.7 million for the nine months ended September 30, 2025, compared to $101.6 million for the same period in 2024[149][150].

Entrada Therapeutics Reports Third Quarter 2025 Financial Results -- Company on track to report ELEVATE-44-201 data from first patient cohort in Q2 2026 -- -- First patient dosed in ELEVATE-45-201 and the Company is on track to report data from the first patient cohort in mid-2026 -- -- Filed for regulatory authorization in U.K. to initiate ELEVATE-50-201, a global Phase 1/2 MAD clinical study of ENTR-601-50 -- -- Expected cash runway extended into Q3 2027 with $327 million in cash, cash equivalents and mar ...

-- Company on track to report ELEVATE-44-201 data from first patient cohort in Q2 2026 -- -- First patient dosed in ELEVATE-45-201 and the Company is on track to report data from the first patient cohort in mid-2026 -- -- Filed for regulatory authorization in U.K. to initiate ELEVATE-50-201, a global Phase 1/2 MAD clinical study of ENTR-601-50 -- -- Expected cash runway extended into Q3 2027 with $327 million in cash, cash equivalents and marketable securities as of September 30, 2025 -- BOSTON, Nov. 06, 20 ...

Core Insights - Entrada Therapeutics, Inc. will participate in two upcoming investor conferences, highlighting its engagement with the investment community [1][2][3] Group 1: Upcoming Events - The CEO, Dipal Doshi, will present at the Jefferies Global Healthcare Conference in London on November 18, 2025, at 5:00 p.m. GMT [2] - Dipal Doshi will also participate in a fireside chat at the 8th Annual Evercore Healthcare Conference on December 3, 2025, at 12:55 p.m. ET in Miami, FL [3] - Live webcasts of these events will be available on the Investor Relations section of the company's website, with replays accessible for 90 days post-event [3] Group 2: Company Overview - Entrada Therapeutics is a clinical-stage biopharmaceutical company focused on developing a new class of medicines targeting intracellular mechanisms previously deemed inaccessible [4] - The company's proprietary Endosomal Escape Vehicle (EEV™) therapeutics aim to enhance the intracellular delivery of various therapeutics, improving the therapeutic index [4] - Entrada is advancing a development portfolio that includes RNA- and protein-based programs for treating neuromuscular and ocular diseases, with lead programs targeting Duchenne muscular dystrophy [4]

Company Overview - Entrada Therapeutics is a clinical stage biotech company focused on transforming patients' lives through innovative therapies [2] - The company has developed a proprietary technology platform known as Endosomal Escape Vehicles (EEVs), which enhances the delivery of therapeutics [2] Technology Platform - EEVs enable access to intracellular targets, which is crucial as approximately 75% of disease targets are intracellular in nature [3] - The unique chemistry of EEVs facilitates improved therapeutic delivery, making it a significant advancement in the biotech field [3] Lead Indications - Entrada's two lead indications are focused on Duchenne Muscular Dystrophy (DMD) and Myotonic Dystrophy Type 1 (DM1), highlighting the company's commitment to addressing serious genetic disorders [2]

Summary of Entrada Therapeutics Update / Briefing Company Overview - **Company**: Entrada Therapeutics (NasdaqGM:TRDA) - **Sector**: Biotechnology - **Focus**: Clinical stage biotech company specializing in neuromuscular diseases, particularly Duchenne muscular dystrophy (DMD) and myotonic dystrophy type 1 (DM1) through its proprietary Endosomal Escape Vehicle (EEV) technology platform [1][4] Key Points and Arguments EEV Technology Platform - **EEV Technology**: Enhances drug delivery to intracellular targets, crucial for diseases where 75% of targets are intracellular [4] - **Mechanism**: EEVs allow for a 50% drug release from endosomes, significantly improving target exposure compared to current therapeutics [5] - **Applications**: Used across DMD programs and partnered DM1 program with Vertex Pharmaceuticals [5][6] Market Opportunity - **DMD Patient Population**: Approximately 40,000 patients in the U.S. and Europe, with specific exon mutations affecting around 35-40% of this population [11][12] - **Exon-Specific Focus**: Targeting exons 44, 45, 50, and 51, with no current approved therapeutics effectively producing dystrophin [12][11] Competitive Landscape - **Comparison with Competitors**: Current exon therapies have not demonstrated adequate clinical benefits due to insufficient target engagement [16][17] - **Regulatory Position**: Entrada's rigorous clinical trial design and data collection may provide a competitive edge in regulatory discussions, especially with the FDA [30][32] Clinical Trials and Data - **Current Trials**: ENTR-601-44 and ENTR-601-45 programs are in double-blinded studies, with initial patient dosing completed [25][26] - **Expected Outcomes**: Anticipated data release in 2026, focusing on safety and dystrophin production [26][27] - **Dosing Regimen**: ENTR-601-44 will have doses of 6, 12, and 18 mg/kg, while ENTR-601-45 will have doses of 5, 10, and 15 mg/kg [26][27] Safety and Efficacy - **Safety Profile**: Previous studies showed no adverse events, indicating a clean safety profile [54] - **Functional Benefit**: Emphasis on translating dystrophin production into functional improvements for patients, such as better mobility [49][50] Future Directions - **Expansion Plans**: Interest in exploring additional exons beyond the current four, contingent on regulatory flexibility [60][62] - **Personalized Medicine**: Aiming to provide tailored treatments for DMD patients, addressing individual needs and safety concerns [41][44] Regulatory Environment - **Regulatory Precedent**: Previous approvals in DMD have set a framework for Entrada's approach, focusing on high-quality data and rigorous clinical trials [36][37] - **Collaboration with Regulatory Agencies**: Strong relationships with regulatory bodies in Europe and the U.S. to facilitate trial execution and data submission [30][32] Additional Important Insights - **Market Dynamics**: The company is positioned to capitalize on the unmet clinical needs in DMD, especially as competitors face challenges [38][39] - **Patient-Centric Approach**: Continuous engagement with patient advocacy groups to align clinical studies with patient needs [15][37] - **Long-Term Vision**: Entrada aims to redefine treatment paradigms in DMD, focusing on safety, efficacy, and quality of life improvements for patients [66][67]

Core Points - Entrada Therapeutics announced the recipients of its third annual DREAMS Grant Program, awarding $50,000 each to Jett Foundation (U.S.) and Parent Project aps (Italy) to support the Duchenne muscular dystrophy community [1][2] - The grants aim to fund projects that enhance equity, accessibility, and inclusion for underrepresented or underserved individuals living with Duchenne [1][2] Group 1: Grant Program Details - The DREAMS Grant Program is designed to support organizations working to identify and reach members of the Duchenne community globally [1][2] - The 2025 grants were announced ahead of World Duchenne Awareness Day on September 7 [1] - Jett Foundation will use the funds to support its Camp Promise program, which focuses on independent living and self-advocacy for individuals aged 18 and older [5] - Parent Project aps will utilize the grant to provide home-based care and teleconsultation services in underserved regions of Southern Italy [5] Group 2: Organizational Commitment - Entrada Therapeutics emphasizes its commitment to the Duchenne community beyond therapeutic development, engaging with patients and families to understand their needs [2] - The expansion of the grant program to include organizations from the U.S., EU, and U.K. reflects this commitment [2] - The independent grant review committee, composed of neuromuscular leaders and advocates, played a crucial role in selecting the grant recipients [4] Group 3: Organizational Background - Jett Foundation is based in Massachusetts and focuses on enriching the lives of individuals affected by Duchenne through family support services and educational initiatives [5] - Parent Project aps, founded by parents, aims to promote scientific research and improve access to care for individuals with Duchenne and Becker muscular dystrophy [5] - Entrada Therapeutics is a clinical-stage biopharmaceutical company developing a new class of medicines targeting intracellular delivery for neuromuscular diseases [6]

Company Performance - Entrada Therapeutics reported a quarterly loss of $1.04 per share, which was worse than the Zacks Consensus Estimate of a loss of $0.86, and a significant decline from earnings of $1.55 per share a year ago, indicating an earnings surprise of -20.93% [1] - The company posted revenues of $1.95 million for the quarter ended June 2025, missing the Zacks Consensus Estimate by 78.02%, and a sharp decline from year-ago revenues of $94.69 million [2] - Over the last four quarters, Entrada Therapeutics has surpassed consensus EPS estimates three times, but has underperformed the market with shares losing about 66.3% since the beginning of the year [2][3] Earnings Outlook - The current consensus EPS estimate for the upcoming quarter is -$0.93 on revenues of $8.54 million, and for the current fiscal year, it is -$3.18 on revenues of $44.01 million [7] - The estimate revisions trend for Entrada Therapeutics was mixed ahead of the earnings release, resulting in a Zacks Rank 3 (Hold) for the stock, suggesting it is expected to perform in line with the market in the near future [6] Industry Context - Entrada Therapeutics operates within the Zacks Medical - Biomedical and Genetics industry, which is currently ranked in the bottom 42% of over 250 Zacks industries, indicating potential challenges for stock performance [8] - Empirical research shows a strong correlation between near-term stock movements and trends in earnings estimate revisions, which can impact investor sentiment and stock performance [5]